Craig M. Pratt, M.D.
B.A. University of California, Los Angeles, CA
Internship, Internal Medicine, University of California, Davis
Dr. Craig Pratt, a clinical cardiologist, serves as medical director of the Cardiac Care Unit and EKG lab, and as director of research in the Methodist DeBakey Heart & Vascular Center at The Methodist Hospital.
Dr. Pratt serves on a number of national and international committees. He is a consultant to the Center for Drug Evaluation and Research for the Food and Drug Administration (FDA); the Cardiovascular and Renal Drugs Advisory Board; and Center for Drug Evaluation and Research, a contributor to the North American Society for Pacing and Electrophysiology and various committees of the National Heart, Lung & Blood Institute. He is a fellow in the American College of Cardiology.
Dr. Pratt is a frequent contributor to publications, having authored over 300 journal articles, books, chapters and abstracts. Dr. Pratt received his medical degree from the University of California - Irvine. He completed residencies in internal medicine and a fellowship in cardiology at the University of California - Davis.
Lieutenant, US Naval Reserve, Camp Pendleton, CA; Director, Hypertension Clinic; Director, Outpatient Medical Services; Medical Advisor to Base General on Marine Weight Loss and Fitness Program; Director, Medical Clinic Services for Vietnam Refugees
Dr. Pratt’s practice is dedicated to advancing cardiac patient care and clinical research. As director of research in the Methodist DeBakey Heart & Vascular Center, he leads and supports a team of physicians that together are today conducting more than 200 clinical studies across a wide range of cardiac-related topics. Dr. Pratt’s specific research interests are in clinical investigation of cardiac arrhythmias.
cardiac arrhythmia, cardiovascular disease
Leja MJ, Case J, Bateman TM, Iskandrian A, Kronenberg MW, Chang SM, Iskander SS, Matthias JA, Strahs KR, Mishra Rg, Kotler ML, Frias ME, Mahmarian JJ, Pratt CM. Nicotine patches are safe to use in patients with coronary artery disease and stress-induced myocardial ischemia. JACC 2007;49:209A.
Pratt CM, Navratil J, Nagy A, Blomstrom P, Butterfield N, Dickinson G, Mangal B, Beatch GN. Oral Vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion. Heart Rhythm 2007;4(5S):S176.
Mahmarian JJ, Pratt CM. Risk stratification after acute myocardial infarction: is it time to reassess? Implications from the INSPIRE trial. J Nucl Cardiol. 2007 May-Jun;14(3):282-92.
Mahmarian JJ, Shaw LJ, Filipchuk NG, Dakik MJ, Keng F, Allam A, Moye LA, Pratt CM. A multinational study to establish the value of early adenosine technetium-99m sestimibi myocardial perfusion imaging in identifying a low-risk group for early hospital discharge following acute myocardial infarction. JACC 2006; 48(12):2448-57.
Mahmarian JJ, Shaw LJ, Flipchuk NG, Dakik MJ, Keng F, Allam A, Moye LA, Pratt, CM. An initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high risk but stable survivors of acute myocardial infarction. JACC 2006; 48(12):2458-67.
Hohnloser SH, Al-Khalidi HR, Pratt CM, Brum JM, Tatla DS, Tchou P, Dorian P. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial. Eur Heart J 2006; 24:3027-32.